Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Bodlet, L. Delaunois, C. Dahlqvist, J. Jamart, G. Maury (Yvoir, Belgium). Does emphysema influence the application of du Bois score in idiopathic pulmonary fibrosis?. Eur Respir J 2012; 40: Suppl. 56, 701

Member's Comments

No comment yet.

Related content which might interest you: Tt anti fibrotiques hors FPI: approche raisonnée / Anti-fibrotic treatments for conditions other than idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020 De novo interstitial fibrosis after pulmonary resection Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease Year: 2008 Does emphysema coexistence with IPF change prognosis? Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Validation of GAP score in Danish patients diagnosed with idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Diffuse parenchymal lung disease II Year: 2013 Subtypes of pulmonary emphysema on HRCT affect prognosis on combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Pirfenidone in idiopathic pulmonary fibrosis - Real life experience from a german tertiary referral centre for interstitial lung diseases Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 The diagnostic role of cryobiopsy in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Interventional procedures for diagnosis of diffuse lung diseases and peripheral pulmonary lesions Year: 2013 The impact of emphysema in pulmonary fibrosis Source: Eur Respir Rev 2013; 22: 153-157 Year: 2013 Item generation for a patient reported outcome measure (PRoM) in idiopathic pulmonary fibrosis (IPF): Application of consensus methods Source: International Congress 2015 – IPF: clinical aspects Year: 2015 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Titrated oxygen requirement and prognostication in idiopathic pulmonary fibrosis Source: Eur Respir J 2012; 39: 359-365 Year: 2012 Idiopathic pulmonary fibrosis (IPF): the patient journey Source: Virtual Congress 2020 – Clinical aspects of idiopathic pulmonary fibrosis Year: 2020 Assessment of nutritional status in patients with idiopathic pulmonary fibrosis Source: International Congress 2016 – Long-term oxygen therapy, noninvasive ventilation, and other clinical variables in chronic lung diseases Year: 2016 Prise en charge de l’aspergillose pulmonaire chronique Chronic pulmonary aspergillosis care Source: International Congress 2017 – French Programme 2017 Year: 2017 Idiopathic pulmonary upper lobe fibrosis shows distinct features and poor prognosis compared to idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease Source: Eur Respir Rev, 27 (150) 180110; 10.1183/16000617.0110-2018 Year: 2018